

# CITATION REPORT

List of articles citing

**A method to determine the optimal intensity of oral anticoagulant therapy**

**DOI: PM/8470047**

**Thrombosis and Haemostasis, 1993, 69, 236-9.**

**Source:** <https://exaly.com/paper-pdf/129995500/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
532	Risk of stroke during long-term anticoagulant therapy in patients after myocardial infarction. <b>1996</b> , 39, 301-7		26
531	Management of anticoagulant therapy: The dutch experience. <i>Journal of Thrombosis and Thrombolysis</i> , <b>1996</b> , 2, 265-269	5.1	4
530	Audit of anticoagulant therapy. <b>1996</b> , 49, 5-9		42
529	A new regimen for starting warfarin therapy in out-patients. <b>1998</b> , 46, 157-61		48
528	Secondary stroke prevention in atrial fibrillation: indications, risks, and benefits. <i>Journal of Thrombosis and Thrombolysis</i> , <b>1999</b> , 7, 61-5	5.1	3
527	Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2000</b> , 9, 283-92	5.1	111
526	Recommendations for patients undertaking self management of oral anticoagulation. <b>2001</b> , 323, 985-9		51
525	Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2003</b> , 15, 197-203	5.1	6
524	Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2003</b> , 15, 213-6	5.1	114
523	SMART: self-management of anticoagulation, a randomised trial [ISRCTN19313375]. <b>2003</b> , 4, 11		13
522	A systematic review of outcome measures reported for the therapeutic effectiveness of oral anticoagulation. <b>2003</b> , 56, 48-51		17
521	External quality assessment for warfarin dosing using computerised decision support software. <b>2003</b> , 56, 605-7		6
520	The relationship between adherence and quality of treatment with vitamin K antagonists. <b>2004</b> , 2, 362-3		2
519	A randomized trial to assess the impact of an antithrombotic decision aid in patients with nonvalvular atrial fibrillation: the DAAFI trial protocol [ISRCTN14429643]. <b>2004</b> , 4, 5		11
518	Personalized versus non-personalized computerized decision support system to increase therapeutic quality control of oral anticoagulant therapy: an alternating time series analysis. <b>2004</b> , 4, 27		10
517	Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?. <b>2005</b> , 59, 582-7		104
516	Patient self-testing is a reliable and acceptable alternative to laboratory INR monitoring. <b>2005</b> , 128, 242-7		91

515	The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481--the Home INR Study (THINRS). <i>Journal of Thrombosis and Thrombolysis</i> , <b>2005</b> , 19, 163-72	5.1	20
514	An examination of the association between therapeutic anticoagulation control and glycemic control for patients with diabetes on oral anticoagulation therapy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2005</b> , 19, 209-12	5.1	5
513	Self management of oral anticoagulation: randomised trial. <b>2005</b> , 331, 1057		88
512	Impact of a patient decision aid on care among patients with nonvalvular atrial fibrillation: a cluster randomized trial. <i>Cmaj</i> , <b>2005</b> , 173, 496-501	3.5	70
511	Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. <b>2005</b> , 91, 472-7		229
510	Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. <b>2005</b> , 112, 1687-91		357
509	Cognitive impairment as determinant for sub-optimal control of oral anticoagulation treatment in elderly patients with atrial fibrillation. <b>2005</b> , 22, 353-60		33
508	Health literacy and anticoagulation-related outcomes among patients taking warfarin. <b>2006</b> , 21, 841-6		127
507	Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. <b>2006</b> , 54, 1231-6		177
506	Management of Chinese patients on warfarin therapy in two models of anticoagulation service - a prospective randomized trial. <b>2006</b> , 62, 601-9		45
505	Monitoring anticoagulation in atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2006</b> , 21, 191-8	5.1	28
504	Worldwide management of oral anticoagulant therapy: the ISAM study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2006</b> , 21, 73-7	5.1	96
503	A "two-step" educational approach for patients taking oral anticoagulants does not improve therapy control. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2006</b> , 22, 185-90	5.1	9
502	Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. <i>Cmaj</i> , <b>2006</b> , 174, 1847-52	3.5	60
501	Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin. <b>2006</b> , 92, 196-200		30
500	Patient self management of oral anticoagulation in routine care in the UK. <b>2007</b> , 60, 1263-7		16
499	The influence of NSAIDs on coumarin sensitivity in patients with CYP2C9 polymorphism after total hip replacement surgery. <b>2007</b> , 11, 123-8		10
498	Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction. <b>2007</b> , 63, 335-43		19

497	Anticoagulation treatment for the reduction of stroke in atrial fibrillation: a cohort study to examine the gap between guidelines and routine medical practice. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2007</b> , 24, 65-72	5.1	40
496	Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). <i>Journal of Thrombosis and Thrombolysis</i> , <b>2007</b> , 23, 83-91	5.1	108
495	Paper-based dosing algorithms for maintenance of warfarin anticoagulation. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2007</b> , 23, 195-8	5.1	12
494	Anticoagulation control in the peri-hospitalization period. <b>2007</b> , 22, 727-35		7
493	Effectiveness of warfarin among patients with cancer. <b>2007</b> , 22, 997-1002		44
492	Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2008</b> , 26, 14-21	5.1	22
491	Determinants and measures of quality in oral anticoagulation therapy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2008</b> , 25, 61-6	5.1	40
490	Quality of anticoagulation and use of warfarin-interacting medications in long-term care: a chart review. <b>2008</b> , 8, 13		37
489	Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients. <b>2008</b> , 6, 1655-62		76
488	Warfarin pharmacogenetics. <b>2008</b> , 28, 1084-97		107
487	Genetic determinants of response to warfarin during initial anticoagulation. <b>2008</b> , 358, 999-1008		436
486	How well does the target INR level maintain in warfarin-treated patients with non-valvular atrial fibrillation?. <b>2009</b> , 50, 83-8		13
485	Effect of an interactive voice response system on oral anticoagulant management. <i>Cmaj</i> , <b>2009</b> , 180, 927-33		18
484	Self-monitoring of oral anticoagulation: does it work outside trial conditions?. <b>2009</b> , 62, 168-71		17
483	Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. <b>2009</b> , 2, 297-304		77
482	Improvement in the regulation of the vitamin K antagonist acenocoumarol after a standard initial dose regimen: prospective validation of a prescription model. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2009</b> , 27, 207-14	5.1	6
481	Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. <b>2009</b> , 24, 656-64		91
480	Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation. <b>2009</b> , 19, 965-71		4

479	Achieved anticoagulation vs prosthesis selection for mitral mechanical valve replacement: a population-based outcome study. <b>2009</b> , 136, 1503-1513	21
478	The net clinical benefit of warfarin anticoagulation in atrial fibrillation. <b>2009</b> , 151, 297-305	471
477	A team-based approach to warfarin management in long term care: a feasibility study of the MEDeINR electronic decision support system. <b>2010</b> , 10, 38	13
476	Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. <b>2010</b> , 11, 108	72
475	Ability of VKORC1 and CYP2C9 to predict therapeutic warfarin dose during the initial weeks of therapy. <b>2010</b> , 8, 95-100	60
474	The quality of warfarin prescribing and monitoring in Veterans Affairs nursing homes. <b>2010</b> , 58, 1475-80	16
473	Warfarin discontinuation after starting warfarin for atrial fibrillation. <b>2010</b> , 3, 624-31	149
472	Prospective alpha allocation in the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. <b>2010</b> , 7, 597-604	17
471	A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. <b>2010</b> , 28, 61-74	76
470	Home management of oral anticoagulation via telemedicine versus conventional hospital-based treatment. <b>2011</b> , 17, 169-76	29
469	Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation. <b>2011</b> , 140, 918-924	24
468	Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. <b>2011</b> , 118, 4992-9	59
467	Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study. <b>2011</b> , 96, 583-9	20
466	Quality measures and benchmarking for warfarin therapy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2011</b> , 31, 242-8	5.1 6
465	Hotline update of clinical trials and registries presented at the at the European Society of Cardiology Congress in Paris 2011. <b>2011</b> , 100, 955-71	3
464	The influence of genetic polymorphisms and interacting drugs on initial response to warfarin in Chinese patients with heart valve replacement. <b>2011</b> , 67, 581-90	10
463	Practice nursed-based, individual and video-assisted patient education in oral anticoagulation--protocol of a cluster-randomized controlled trial. <b>2011</b> , 12, 17	14
462	Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic. <b>2011</b> , 12, 88	50

461	Using highly variable warfarin dosing to identify patients at risk for adverse events. <b>2011</b> , 9, 14	1
460	The business case for quality improvement: oral anticoagulation for atrial fibrillation. <b>2011</b> , 4, 416-24	38
459	A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. <b>2012</b> , 186, 88-95	350
458	Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. <b>2012</b> , 12, 417-24	57
457	Incidence rates in dynamic populations. <b>2012</b> , 41, 1472-9	60
456	Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. <b>2012</b> , 119, 861-7	56
455	Efficiency and effectiveness of the use of an acenocoumarol pharmacogenetic dosing algorithm versus usual care in patients with venous thromboembolic disease initiating oral anticoagulation: study protocol for a randomized controlled trial. <b>2012</b> , 13, 239	12
454	Organizational characteristics of high- and low-performing anticoagulation clinics in the Veterans Health Administration. <b>2012</b> , 47, 1541-60	29
453	A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case-control study. <b>2012</b> , 12, 49	14
452	Effects of computer-assisted oral anticoagulant therapy. <b>2012</b> , 10, 17	8
451	Primary care management for optimized antithrombotic treatment [PICANT]: study protocol for a cluster-randomized controlled trial. <b>2012</b> , 7, 79	10
450	The effect of cognitive impairment in the elderly on the initial and long-term stability of warfarin therapy. <b>2012</b> , 29, 307-17	9
449	Benchmark for time in therapeutic range in venous thromboembolism: a systematic review and meta-analysis. <b>2012</b> , 7, e42269	64
448	The Creating an Optimal Warfarin Nomogram (CROWN) Study. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 107, 59-68	7 13
447	Patterns of warfarin use and subsequent outcomes in atrial fibrillation in primary care practices. <b>2012</b> , 8, 587-98	16
446	Warfarin and aspirin in patients with heart failure and sinus rhythm. <b>2012</b> , 366, 1859-69	416
445	Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <b>2012</b> , 141, e44S-e88S	1112
444	Prospective pilot trial of PerMIT versus standard anticoagulation service management of patients initiating oral anticoagulation. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 561-9	7 29

443	Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand. <b>2012</b> , 34, 105-12		40
442	Comparing effectiveness of two anticoagulation management models in a Malaysian tertiary hospital. <b>2013</b> , 35, 736-43		21
441	Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centers and anticoagulation clinics. <b>2013</b> , 13, 85		13
440	Identifying the risks of anticoagulation in patients with substance abuse. <b>2013</b> , 28, 1333-9		10
439	Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. <b>2013</b> , 67, 516-26		16
438	A pharmacogenetic versus a clinical algorithm for warfarin dosing. <b>2013</b> , 369, 2283-93		547
437	Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. <b>2013</b> , 166, 435-41		13
436	Describing the profile of patients on concurrent rifampin and warfarin therapy in western Kenya: a case series. <b>2013</b> , 13, 191-7		12
435	Use of vitamin K antagonist therapy in geriatrics: a French national survey from the French Society of Geriatrics and Gerontology (SFGG). <b>2013</b> , 30, 1019-28		12
434	A Bayesian dose-individualization method for warfarin. <b>2013</b> , 52, 59-68		34
433	Use of warfarin for venous thromboembolism prophylaxis following knee and hip arthroplasty: results of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2). <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 35, 10-4	5.1	12
432	Clinical validation of a new algorithm for computerized dosing of vitamin K antagonist therapy: a retrospective simulation study. <b>2013</b> , 8, 55-63		
431	Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvement. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2013</b> , 35, 333-5	5.1	37
430	Limited English proficient patients and time spent in therapeutic range in a warfarin anticoagulation clinic. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e000170	6	15
429	Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e000067	6	145
428	Vitamin E serum levels and bleeding risk in patients receiving oral anticoagulant therapy: a retrospective cohort study. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e000364	6	27
427	Applying the triple aim to the quality agenda for anticoagulation care. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e000377	6	1
426	Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). <b>2013</b> , 34, 1498-505		97

425	A Pharmacist-Led Point-of-Care INR Clinic: Optimizing Care in a Family Health Team Setting. <b>2013</b> , 2013, 691454		14
424	Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. <i>Journal of the American Heart Association</i> , <b>2013</b> , 2, e000535	6	76
423	Gaps in monitoring during oral anticoagulation: insights into care transitions, monitoring barriers, and medication nonadherence. <b>2013</b> , 143, 751-757		40
422	Dietary vitamin K intake and anticoagulation control during the initiation phase of warfarin therapy: a prospective cohort study. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 110, 195-6	7	5
421	Demonstration of anticoagulation patient self-testing feasibility at an Indian Health Service facility: A case series analysis. <b>2013</b> , 11, 30-7		1
420	Management of stroke prevention in canadian patients with atrial fibrillation at moderate to high risk of stroke. <b>2013</b> , 66, 296-303		1
419	Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. <b>2013</b> , 8, e74037		131
418	Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: efficacy and safety in a nationwide long-term prospective cohort study. <b>2014</b> , 9, e95761		22
417	Educating orally anticoagulated patients in drug safety: a cluster-randomized study in general practice. <b>2014</b> , 111, 607-14		15
416	Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study. <b>2014</b> , 7, 891		31
415	Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review. <i>BMJ Open</i> , <b>2014</b> , 4, e005379	3	1
414	An audit of anticoagulant management to assess anticoagulant control using decision support software. <i>BMJ Open</i> , <b>2014</b> , 4, e005864	3	8
413	Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data. <i>BMJ Open</i> , <b>2014</b> , 4, e004071	3	18
412	Oral anticoagulants for Asian patients with atrial fibrillation. <b>2014</b> , 11, 290-303		27
411	Bleeding rates in Veterans Affairs patients with atrial fibrillation who switch from warfarin to dabigatran. <b>2014</b> , 127, 1179-85		42
410	Qualit� della terapia con dicumarolici, nuovi anticoagulanti orali, e ruolo dei centri per la terapia anticoagulante. <b>2014</b> , 10, 204-211		
409	Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. <b>2014</b> , 12, 24		37
408	Sex differences in treatment quality of self-managed oral anticoagulant therapy: 6,900 patient-years of follow-up. <b>2014</b> , 9, e113627		20



407	Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial. <i>Journal of the American Heart Association</i> , <b>2014</b> , 3, e000521	6	80
406	Cluster randomized controlled trial of a simple warfarin maintenance dosing algorithm versus usual care among primary care practices. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2014</b> , 37, 435-42	5.1	9
405	Bleeding risk with triple antithrombotic therapy in patients with atrial fibrillation and drug-eluting stents. <b>2014</b> , 29, 193-9		13
404	Outcomes of anticoagulation therapy in patients with mental health conditions. <b>2014</b> , 29, 855-61		25
403	Direct vitamin K antagonist anticoagulant treatment health care costs in patients with non-valvular atrial fibrillation. <b>2014</b> , 14, 46		9
402	Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <b>2014</b> , 167, 735-42.e2		80
401	Bleeding complications related to warfarin treatment: a descriptive register study from the anticoagulation clinic at Helsingborg Hospital. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2014</b> , 38, 98-104	5.1	13
400	Association of quality of life with anticoagulant control in patients with heart failure: the Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial. <b>2014</b> , 177, 715-7		2
399	Influence of regular physical activity on warfarin dose and risk of hemorrhagic complications. <b>2014</b> , 34, 545-54		12
398	Pharmacogenetics of warfarin in a paediatric population: time in therapeutic range, initial and stable dosing and adverse effects. <b>2014</b> , 14, 542-8		15
397	Adherence to warfarin treatment among patients with atrial fibrillation. <b>2014</b> , 103, 998-1005		41
396	Bleeding events and associated factors in a cohort of adult patients taking warfarin in Sarawak, Malaysia. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2014</b> , 38, 226-34	5.1	4
395	Anticoagulation in atrial fibrillation. <b>2014</b> , 348, g2116		49
394	A prospective validation of the SAME-TT2R 2 score: how to identify atrial fibrillation patients who will have good anticoagulation control on warfarin. <b>2014</b> , 9, 443-7		51
393	The clinical impact of different coagulometers on patient outcomes. <b>2014</b> , 31, 639-56		6
392	Anticoagulation Management of Atrial Fibrillation: The Relationship of Prevailing Adherence to a Dose Protocol and Recall Schedule on TTR in Primary Care. <b>2014</b> , 1, 2333392814552524		
391	Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism. <b>2015</b> , 100, 188-93		14
390	Cohort study of Anticoagulation Self-Monitoring (CASM): a prospective study of its effectiveness in the community. <i>British Journal of General Practice</i> , <b>2015</b> , 65, e428-37	1.6	9

389	Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: A single-center observational study. <b>2015</b> , 31, 339-44		41
388	Predictors of Thromboembolic Events in Patients with Ventricular Assist Device. <b>2015</b> , 61, 640-7		17
387	Association Between Usual Vitamin K Intake and Anticoagulation in Patients Under Warfarin Therapy. <b>2015</b> , 4, 235-41		7
386	Factors associated with ischemic stroke on therapeutic anticoagulation in patients with nonvalvular atrial fibrillation. <b>2015</b> , 56, 410-7		8
385	Factors affecting the quality of anticoagulation with warfarin: experience of one cardiac centre. <b>2015</b> , 12, 334-40		11
384	The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. <b>2015</b> , 10, e0124719		38
383	Center-Related Determinants of VKA Anticoagulation Quality: A Prospective, Multicenter Evaluation. <b>2015</b> , 10, e0144314		12
382	New educational approach for patients on warfarin improves knowledge and therapy control. <b>2015</b> , 127, 472-6		4
381	The Impact of Inpatient Versus Outpatient Initiation on Early Warfarin Dosing. <b>2015</b> , 15, 267-74		0
380	Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors. <b>2015</b> , 29, 257-64		2
379	To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort. <b>2015</b> , 10, 795-804		17
378	Quality of Anticoagulation With Vitamin K Antagonists. <b>2015</b> , 38, 357-64		54
377	Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial. <i>Journal of the American Heart Association</i> , <b>2015</b> , 4, e001349	6	6
376	Stroke and Bleeding Risk Associated With Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation in Clinical Practice. <i>Journal of the American Heart Association</i> , <b>2015</b> , 4,	6	12
375	The changing characteristics of atrial fibrillation patients treated with warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2015</b> , 40, 488-93	5.1	4
374	Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). <b>2015</b> , 131, 488-94		179
373	Effectiveness and safety of therapy with vitamin K antagonists in Italian patients aged 80 years or older: a multicentre retrospective study comparing the Zeus algorithm with the PARMA algorithm or manual therapy. <b>2015</b> , 32, 235-41		
372	The criteria of the Italian Federation of Thrombosis Centres on DOACs: a "real world" application in nonvalvular atrial fibrillation patients already on vitamin K antagonist. <b>2015</b> , 10, 157-63		8

371	Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation. <b>2015</b> , 37, 53-9		25
370	Utility of a dedicated pediatric cardiac anticoagulation program: the Boston Children's Hospital experience. <b>2015</b> , 36, 842-50		12
369	Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy. <b>2015</b> , 8, 504-9		18
368	Quality of oral anticoagulation with phenprocoumon in regular medical care and its potential for improvement in a telemedicine-based coagulation service--results from the prospective, multi-center, observational cohort study thrombEVAL. <b>2015</b> , 13, 14		31
367	Meta-analysis of Randomized Controlled Trials of Genotype-Guided vs Standard Dosing of Warfarin. <b>2015</b> , 148, 701-710		20
366	International normalized ratio stability in warfarin-experienced patients with nonvalvular atrial fibrillation. <b>2015</b> , 15, 205-11		27
365	Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. <i>Journal of the American Heart Association</i> , <b>2015</b> , 4, e001486	6	143
364	Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE. <b>2015</b> , 24, 1087-94		57
363	Evaluation of Time in Therapeutic Range on Warfarin Therapy Between Face-to-Face and Telephone Follow-Up in a VA Medical Center. <b>2015</b> , 31, 78-83		9
362	Effect of distance to health facility on the maintenance of INR therapeutic ranges in rheumatic heart disease patients from Cape Town: no evidence for an association. <b>2015</b> , 15, 219		7
361	Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina. <b>2015</b> , 5, 52		5
360	The impact of frequency of patient self-testing of prothrombin time on time in target range within VA Cooperative Study #481: The Home INR Study (THINRS), a randomized, controlled trial. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2015</b> , 40, 17-25	5.1	13
359	Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. <b>2015</b> , 30, 17-24		49
358	Advantages of a Warfarin Protocol for Long-term Care Pharmacists: a Retrospective Cohort Study. <b>2016</b> , 19, 40-9		4
357	Relationship Between Anticoagulation Intensity and Thrombotic or Bleeding Outcomes Among Outpatients With Continuous-Flow Left Ventricular Assist Devices. <b>2016</b> , 9,		65
356	Developing a Complex Educational-Behavioural Intervention: The TREAT Intervention for Patients with Atrial Fibrillation. <b>2016</b> , 4,		5
355	The Use of Fish Oil with Warfarin Does Not Significantly Affect either the International Normalised Ratio or Incidence of Adverse Events in Patients with Atrial Fibrillation and Deep Vein Thrombosis: A Retrospective Study. <b>2016</b> , 8,		8
354	Educational Level, Anticoagulation Quality, and Clinical Outcomes in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study. <b>2016</b> , 11, e0162108		4

353	Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists. <b>2016</b> , 11, e0164485		11
352	Impact of age on long-term anticoagulation and how gender and monitoring setting affect it: implications for decision making and patient management. <b>2016</b> , 82, 1076-83		9
351	Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	12
350	Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients with low time in therapeutic range - study protocol for a randomized controlled trial. <b>2016</b> , 16, 224		4
349	Assessment of psychometric properties of the Brazilian version of the oral anticoagulation knowledge test. <b>2016</b> , 14, 96		6
348	Effect of medication timing on anticoagulation stability in users of warfarin (the INRange RCT): study protocol for a randomized controlled trial. <b>2016</b> , 17, 391		2
347	Impact of Blood Pressure Control on Thromboembolism and Major Hemorrhage in Patients With Nonvalvular Atrial Fibrillation: A Subanalysis of the J-RHYTHM Registry. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	30
346	Improving stroke prevention therapy for patients with atrial fibrillation in primary care: protocol for a pragmatic, cluster-randomized trial. <b>2016</b> , 11, 159		10
345	Antithrombotic stewardship: a multidisciplinary team approach towards improving antithrombotic therapy outcomes during and after hospitalisation: a study protocol. <i>BMJ Open</i> , <b>2016</b> , 6, e011537	3	5
344	A real world data of dabigatran etexilate: multicenter registry of oral anticoagulants in nonvalvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2016</b> , 42, 399-404	5.1	15
343	Plasma Vitamin K1 Levels in Italian Patients Receiving Oral Anticoagulant Therapy for Mechanical Heart Prosthesis: A Case-Control Study. <b>2016</b> , 16, 267-274		2
342	A systematic review on comparing 2 common models for management of warfarin therapy; pharmacist-led service versus usual medical care. <b>2016</b> , 56, 24-38		33
341	Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. <b>2016</b> , 39, 555-564		58
340	Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists. <b>2016</b> , 21, 41		9
339	Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. <b>2016</b> , 353, i2868		86
338	Platelet-Monocyte Aggregates and C-Reactive Protein are Associated with VTE in Older Surgical Patients. <i>Scientific Reports</i> , <b>2016</b> , 6, 27478	4.9	16
337	Genetic determinants of variability in warfarin response after the dose-titration phase. <b>2016</b> , 26, 510-516		3
336	Cost of vitamin K antagonist anticoagulant treatment in patients with metallic prosthetic valve in mitral position. <b>2016</b> , 4, 2050312116663123		1

335	Anticoagulated patient's perception of their illness, their beliefs about the anticoagulant therapy prescribed and the relationship with adherence: impact of novel oral anticoagulant therapy - study protocol for The Switching Study: a prospective cohort study. <b>2016</b> , 16, 22		5
334	The safety and efficacy of vitamin K antagonist in atrial fibrillation patients with previous ulcer bleeding: Long-term results from a multicenter study. <b>2016</b> , 95, e5467		6
333	Risk of major bleeding at different PT-INR ranges in elderly Japanese patients with non-valvular atrial fibrillation receiving warfarin: a nested case-control study. <b>2016</b> , 2, 2		5
332	How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation?. <b>2016</b> , 118, 697-9		9
331	Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. <b>2016</b> , 8, 309-316		28
330	Quality of anticoagulation control among patients with atrial fibrillation: An experience of a tertiary care center in Saudi Arabia. <b>2016</b> , 28, 239-43		7
329	Effect of Left Ventricular Systolic Dysfunction on Response to Warfarin. <b>2016</b> , 118, 232-6		3
328	Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. <b>2016</b> , 14, 14		27
327	Cost-effectiveness of pharmacogenetic-guided dosing of warfarin in the United Kingdom and Sweden. <b>2016</b> , 16, 478-84		19
326	Home management of INR in the public health system: feasibility of self-management of oral anticoagulation and long-term performance of individual POC devices in determining INR. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2016</b> , 42, 146-53	5.1	4
325	Effects of anticoagulation provider continuity on time in therapeutic range for warfarin patients. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2016</b> , 42, 283-7	5.1	4
324	Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. <i>Journal of the American Heart Association</i> , <b>2016</b> , 5,	6	261
323	Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users. <b>2016</b> , 36, 263-72		20
322	Bleeding complications in venous thrombosis patients on well-managed warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2016</b> , 41, 351-8	5.1	13
321	Patient adherence to warfarin therapy and its impact on anticoagulation control. <b>2016</b> , 24, 29-34		29
320	Effectiveness and safety of dabigatran versus acenocoumarol in real-world patients with atrial fibrillation. <b>2016</b> , 18, 1319-27		27
319	Incidence and Determinants of Traumatic Intracranial Bleeding Among Older Veterans Receiving Warfarin for Atrial Fibrillation. <b>2016</b> , 1, 65-72		23
318	Warfarin Dosing Algorithms and the Need for Human Intervention. <b>2016</b> , 129, 431-7		7

317	Diabetes mellitus is associated with increased bleeding in pulmonary embolism receiving conventional anticoagulant therapy: findings from a "real-world" study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2017</b> , 43, 540-549	5.1	13
316	SAMe-TTR predicts quality of anticoagulation in patients with acute venous thromboembolism: The MAQI experience. <b>2017</b> , 22, 197-203		10
315	Synergic impact of oral anticoagulation control and renal function in determining major adverse events in atrial fibrillation patients undergoing percutaneous coronary intervention: insights from the AFCAS registry. <b>2017</b> , 106, 420-427		4
314	Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System. <b>2017</b> , 15, 657-667		9
313	Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	41
312	Health literacy and warfarin therapy at two anticoagulation clinics in Brazil. <b>2017</b> , 103, 1089-1095		16
311	A hemodialysis cohort study of protocol-based anticoagulation management. <b>2017</b> , 10, 66		2
310	Warfarin utilisation and anticoagulation control in patients with atrial fibrillation and chronic kidney disease. <b>2017</b> , 103, 818-826		53
309	Reduced anticoagulation variability in patients on warfarin monitored with Fiix-prothrombin time associates with reduced thromboembolism: The Fiix-trial. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2017</b> , 43, 550-561	5.1	5
308	Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2017</b> , 44, 38-47	5.1	15
307	Association Between Patient-Reported Medication Adherence and Anticoagulation Control. <b>2017</b> , 130, 1092-1098.e2		9
306	Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. <b>2017</b> , 12, 1109-1119		25
305	Improvement of time in therapeutic range with warfarin by pharmaceutical intervention. <b>2017</b> , 39, 41-44		5
304	Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	4
303	Anticoagulation Control in Patients With Ventricular Assist Devices. <b>2017</b> , 63, 759-765		16
302	C2238 ANP gene variant promotes increased platelet aggregation through the activation of Nox2 and the reduction of cAMP. <i>Scientific Reports</i> , <b>2017</b> , 7, 3797	4.9	7
301	[Prevalence of oral anticoagulation and quality of its management in primary healthcare: A study by the Health Sentinel Network of the Region of Valencia (Spain)]. <b>2017</b> , 49, 534-548		8
300	Effectiveness and safety of dabigatran warfarin in "real-world" Japanese patients with atrial fibrillation: A single-center observational study. <b>2017</b> , 33, 107-110		8

299	Transition of stable patients from traditional anticoagulation clinic services to telephonic management. <b>2017</b> , 39, 569-572		9
298	Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. <b>2017</b> , 4, CD008600		31
297	PORTALS: design of an innovative approach to anticoagulation management through eHealth. <b>2017</b> , 17, 213		4
296	Effect of a combined education and eHealth programme on the control of oral anticoagulation patients (PORTALS study): a parallel cohort design in Dutch primary care. <i>BMJ Open</i> , <b>2017</b> , 7, e017909	3	8
295	Assessment of oral anticoagulation control at two pharmacist-managed clinics in Brazil. <b>2017</b> , 39, 1157-1161		12
294	Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial. <b>2017</b> , 318, 1115-1124		142
293	Influence of Kidney Transplant Status on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. <b>2017</b> , 37, 1366-1373		3
292	Clinical Prediction Model for Time in Therapeutic Range While on Warfarin in Newly Diagnosed Atrial Fibrillation. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	12
291	Atrial fibrillation decision support tool: Population perspective. <b>2017</b> , 194, 49-60		7
290	Quality of anticoagulation control and hemorrhage risk among African American and European American warfarin users. <b>2017</b> , 27, 347-355		18
289	A randomized trial of restarting warfarin at maintenance versus loading doses following an elective procedure. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2017</b> , 44, 507-515	5.1	2
288	Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. <i>Scientific Reports</i> , <b>2017</b> , 7, 12066	4.9	14
287	Designing and Implementing an Electronic Patient Registry to Improve Warfarin Monitoring in the Ambulatory Setting. <i>Joint Commission Journal on Quality and Patient Safety</i> , <b>2017</b> , 43, 353-360	1.4	1
286	Vitamin K antagonists in the era of direct oral anticoagulants: is there still a room for their use?. <b>2017</b> , 12, 1087-1089		1
285	Personalized Anticoagulation: Optimizing Warfarin Management Using Genetics and Simulated Clinical Trials. <b>2017</b> , 10,		4
284	Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach. <b>2017</b> , 101, 675-683		20
283	Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2017</b> , 43, 283-288	5.1	15
282	Effect of oral anticoagulant therapy on mortality in end-stage renal disease patients with atrial fibrillation: a prospective study. <b>2017</b> , 30, 573-581		18

281	Anticoagulation Stability Depends on CHADS Score and Hepatorenal Function in Warfarin-treated Patients, Including Those with Atrial Fibrillation. <b>2017</b> , 24, 68-76		5
280	The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study. <b>2017</b> , 34, 349-355		4
279	Sociodemographic factors in patients continuing warfarin vs those transitioning to direct oral anticoagulants. <b>2017</b> , 1, 2536-2540		3
278	Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. <b>2017</b> , 10, 135-143		64
277	Effect of Standardized Warfarin Treatment Protocol on Anticoagulant Effect: Comparison of a Warfarin Medication Therapy Adherence Clinic with Usual Medical Care. <b>2017</b> , 8, 637		14
276	SAMe-TT2R2 Score in the Outpatient Anticoagulation Clinic to Predict Time in Therapeutic Range and Adverse Events. <b>2017</b> , 108, 290-296		7
275	Quality of Anticoagulation with Warfarin in Korean Patients with Atrial Fibrillation and Prior Stroke: A Multicenter Retrospective Observational Study. <b>2017</b> , 13, 273-280		22
274	Obesity is not associated with recurrent venous thromboembolism in elderly patients: Results from the prospective SWITCO65+ cohort study. <b>2017</b> , 12, e0184868		3
273	Time to Revisit the Time in the Therapeutic Range. <i>Journal of Atrial Fibrillation</i> , <b>2017</b> , 9, 1569	0.8	5
272	A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation: A randomized clinical trial in primary care. <b>2018</b> , 97, e9578		4
271	Anxiety, Depression, and Adverse Clinical Outcomes in Patients With Atrial Fibrillation Starting Warfarin: Cardiovascular Research Network WAVE Study. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	6	20
270	Quality of Anticoagulation With Warfarin at a Tertiary Hospital in Botswana. <b>2018</b> , 24, 596-601		19
269	Use of neutrophil-lymphocyte ratio for risk stratification and relationship with time in therapeutic range in patients with nonvalvular atrial fibrillation: A pilot study. <b>2018</b> , 41, 339-342		5
268	Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. <b>2018</b> , 41, 576-585		10
267	Influence of Age on Warfarin Dose, Anticoagulation Control, and Risk of Hemorrhage. <b>2018</b> , 38, 588-596		23
266	Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial. <b>2018</b> , 74, 571-582		2
265	Time in therapeutic range and stability over time for warfarin users in clinical practice: a retrospective cohort study using linked routinely collected health data in Alberta, Canada. <i>BMJ Open</i> , <b>2018</b> , 8, e016980	3	14
264	Association between satisfaction with and adherence to warfarin therapy on the control of international normalized ratio: A hospital-based study in Saudi Arabia. <b>2018</b> , 26, 145-149		11



263	Efficacy of Warfarin Anticoagulation and Incident Dementia in a Community-Based Cohort of Atrial Fibrillation. <b>2018</b> , 93, 145-154		34
262	Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE-CIRCUIT trial. <b>2018</b> , 34, 148-157		3
261	Erythrocyte compression index is impaired in patients with residual vein obstruction. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 46, 31-38	5.1	3
260	Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. <b>2018</b> , 39, 2942-2955		121
259	Real-world antithrombotic therapies and clinical outcomes after second-generation drug-eluting stent implantation in patients with atrial fibrillation: a multi-center cohort study. <b>2018</b> , 33, 986-996		1
258	Effectiveness and safety of oral anticoagulants in patients with sickle cell disease and venous thromboembolism: a retrospective cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 45, 512-515		8
257	Data on incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants. <b>2018</b> , 17, 830-836		5
256	Potential Causes and Implications of Low Target Therapeutic Ratio in Warfarin-Treated Patients for Thrombosis Prophylaxis: A Single-Center Experience. <b>2018</b> , 24, 536-541		1
255	Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation. <b>2018</b> , 18, 907-915		67
254	[Fine-tuning of antithrombotic therapy in patients with non-valvular atrial fibrillation. The AFINVA register]. <b>2018</b> , 50, 340-349		2
253	Validation of knowledge and adherence assessment tools among patients on warfarin therapy in a Saudi hospital anticoagulant clinic. <b>2018</b> , 40, 56-66		11
252	Improving warfarin therapy through implementation of a hospital-based pharmacist managed clinic in Jamaica. <b>2018</b> , 16, 1214		2
251	Role of Red Cell Distribution Width in the Relationship between Clinical Outcomes and Anticoagulation Response in Patients with Atrial Fibrillation. <b>2018</b> , 54, 113-120		5
250	Low Performance of a Clinical-Genetic Model in the Estimation of Time in Therapeutic Range in Acenocoumarol-Adherent Patients with Nonvalvular Atrial Fibrillation: The Quality of Anticoagulation Challenge. <b>2018</b> , 2018, 8012747		1
249	Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II. <b>2018</b> , 3, 1174-1182		58
248	Risk of reoperation in bioprosthetic valve patients with indication for long-term anticoagulation. Results from the observational retrospective multicentre PLECTRUM study. <b>2018</b> , 5, e000837		3
247	Triple therapy after PCI - Warfarin treatment quality and bleeding risk. <b>2018</b> , 13, e0209187		2
246	Rivaroxaban versus Warfarin in Patients with Mechanical Heart Valve: Rationale and Design of the RIWA Study. <b>2018</b> , 18, 303-308		11

245	Pharmaceutical Care Increases Time in Therapeutic Range of Patients With Poor Quality of Anticoagulation With Warfarin. <b>2018</b> , 9, 1052		11
244	Reduced incidence of vein occlusion and postthrombotic syndrome after immediate compression for deep vein thrombosis. <b>2018</b> , 132, 2298-2304		27
243	Time in the Therapeutic Range for Assessing Anticoagulation Quality in Patients Receiving Continuous Unfractionated Heparin. <b>2018</b> , 24, 178S-181S		5
242	Antithrombotic treatments in patients with acute ischemic stroke and non-valvular atrial fibrillation before introduction of non-vitamin K antagonist oral anticoagulants into practice in Korea. <b>2018</b> , 13, e0202803		2
241	Portable coagulometer for vitamin K-antagonist monitoring: the patients' point of view. <b>2018</b> , 12, 1521-1526		8
240	Improving anticoagulation of patients with an implantable left ventricular assist device. <b>2018</b> , 7, e000250		6
239	Predictive ability of scores for bleeding risk in heart disease outpatients on warfarin in Brazil. <b>2018</b> , 13, e0205970		2
238	Long-Term Statin Administration Does Not Affect Warfarin Time in Therapeutic Range in Australia or Singapore. <b>2018</b> , 7,		3
237	Time spent at blood pressure target and the risk of death and cardiovascular diseases. <b>2018</b> , 13, e0202359		2
236	Quality of Chronic Anticoagulation Control in Patients with Intracranial Haemorrhage due to Vitamin K Antagonists. <b>2018</b> , 2018, 5613103		1
235	Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e008987	6	59
234	Bivalirudin for left ventricular assist device thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 46, 496-501	5.1	6
233	Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7, e008755	6	10
232	Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry. <b>2018</b> , 4, 59-68		22
231	Effects of vitamin K epoxide reductase complex 1 gene polymorphisms on warfarin control in Japanese patients with left ventricular assist devices (LVAD). <b>2018</b> , 74, 885-894		2
230	An Exploratory Study of Daprodustat in Erythropoietin-Hyporesponsive Subjects. <b>2018</b> , 3, 841-850		16
229	Sustained atrial fibrillation increases the risk of anticoagulation-related bleeding in heart failure. <b>2018</b> , 107, 1170-1179		2
228	Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQI) registry to the RE-LY, ROCKET-AF, and ARISTOTLE trials. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 46, 316-321	5.1	9

227	Outcomes of warfarin therapy managed by pharmacists via hospital anticoagulation clinic versus online anticoagulation clinic. <b>2018</b> , 40, 1072-1077		9
226	Thromboprophylaxis for Patients with High-risk Atrial Fibrillation and Flutter Discharged from the Emergency Department. <b>2018</b> , 19, 346-360		9
225	Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer. <b>2018</b> , 48, 406-417		26
224	Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial. <b>2018</b> , 16, 104		22
223	Assessment of patients' warfarin knowledge and anticoagulation control at a joint physician- and pharmacist-managed clinic in China. <b>2018</b> , 12, 783-791		8
222	Efficacy and safety of dabigatran versus warfarin from the RE-LY trial. <b>2018</b> , 5, e000800		8
221	Pharmacist interventions improve time in therapeutic range of elderly rural patients on warfarin therapy: a randomized trial. <b>2018</b> , 40, 1078-1085		12
220	Associations between illness beliefs, medication beliefs, anticoagulation-related quality of life, and INR control: Insights from the Switching Study. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2018</b> , 2, 497-507	5.1	12
219	Warfarin control in patients transitioning to warfarin after non-vitamin K oral anticoagulant (NOAC) therapy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 46, 461-465	5.1	4
218	A Standardized Telephone Intervention Algorithm Improves the Survival of Ventricular Assist Device Outpatients. <b>2018</b> , 42, 961-969		9
217	Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation. <b>2018</b> , 13, 1144-1152		29
216	Warfarin anticoagulation in hemodialysis patients with atrial fibrillation: comparison of nephrologist-led and anticoagulation clinic-led management. <b>2018</b> , 19, 4		5
215	A multicenter, prospective study evaluating the impact of the clinical pharmacist-physician counselling on warfarin therapy management in Lebanon. <b>2018</b> , 18, 80		8
214	Moving anticoagulation initiation and monitoring services into the community: evaluation of the Brighton and Hove community pharmacy service. <b>2018</b> , 18, 91		16
213	Time in Therapeutic Range of Oral Vitamin K Antagonists in Hospitalized Elderly Patients. <b>2018</b> , 35, 569-574		0
212	Clinical usefulness of the SAME-TT2R2 score: A systematic review and simulation meta-analysis. <b>2018</b> , 13, e0194208		8
211	Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial). <b>2018</b> , 122, 821-827		2
210	A prospective, multi-center cohort study: investigating the ability of warfarin-treated patients to predict their INR. <b>2019</b> , 108, 212-217		3

209	Impact of an electronic medium delivery of warfarin education in a low income, minority outpatient population: a pilot intervention study. <b>2019</b> , 19, 1050	3
208	Differences in the quality of oral anticoagulation therapy with vitamin K antagonists in German GP practices - results of the cluster-randomized PICANT trial (Primary Care Management for Optimized Antithrombotic Treatment). <b>2019</b> , 19, 539	0
207	Polymorphisms of and genes related to time in therapeutic range in patients with atrial fibrillation using warfarin. <b>2019</b> , 12, 151-159	5
206	Long-term effectiveness and safety of self-management of oral anticoagulants in real-world settings. <b>2019</b> , 19, 186	0
205	Reliability and validity of the Maltese version of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). <b>2019</b> , 13, 969-979	4
204	The SAME-TTR Score Predicts Warfarin Control in an Australian Population with Atrial Fibrillation. <b>2019</b> , 8,	6
203	Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. <b>2019</b> , 4, 756-764	7
202	Validation and psychometric properties of the Maltese version of the Duke Anticoagulation Satisfaction Scale (DASS). <b>2019</b> , 12, 741-752	3
201	Use of simplified HAS-BLED score in patients with atrial fibrillation receiving warfarin. <b>2019</b> , 35, 711-715	1
200	Evaluation of oral anticoagulants in atrial fibrillation patients over 80 years of age with nonsevere frailty. <b>2019</b> , 35, 795-803	8
199	Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment. <b>2019</b> , 8,	20
198	Standardized warfarin monitoring decreases adverse drug reactions. <b>2019</b> , 20, 151	2
197	Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: a cross-sectional study. <b>2019</b> , 13, 1363-1373	16
196	Effect of Low-Intensity vs Standard-Intensity Warfarin Prophylaxis on Venous Thromboembolism or Death Among Patients Undergoing Hip or Knee Arthroplasty: A Randomized Clinical Trial. <b>2019</b> , 322, 834-842	5
195	First evidence for a pharmacist-led anticoagulant clinic in a medicare part A long term care environment. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 690-693	5.1 1
194	Personalised Warfarin Dosing in Children Post-cardiac Surgery. <b>2019</b> , 40, 1735-1744	4
193	Oral anticoagulation in very elderly patients with atrial fibrillation: Results from the prospective multicenter START2-REGISTER study. <b>2019</b> , 14, e0216831	12
192	The effect of simvastatin on warfarin anticoagulation: a Swedish register-based nationwide cohort study. <b>2019</b> , 75, 1387-1392	4

191	Oral anticoagulant use and clinical outcomes in elderly Japanese patients: findings from the SAKURA AF Registry. <b>2019</b> , 34, 2021-2030			6
190	Safety and Efficacy of Minimally Interrupted Dabigatran vs Uninterrupted Warfarin Therapy in Adults Undergoing Atrial Fibrillation Catheter Ablation: A Randomized Clinical Trial. <b>2019</b> , 2, e191994			29
189	Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. <b>2019</b> , 40, 3013-3021			75
188	Optimal INR level for warfarin therapy after mechanical mitral valve replacement. <b>2019</b> , 19, 97			2
187	Patient compliance with an anticoagulation management system based on a smartphone application. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 263-269	5.1		4
186	Implementation of genotype-guided dosing of warfarin with point-of-care genetic testing in three UK clinics: a matched cohort study. <b>2019</b> , 17, 76			22
185	International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 27-34	5.1		4
184	Anticoagulation Management With Coumarinic Drugs in Chilean Patients. <b>2019</b> , 25, 1076029619834342			3
183	The comparison of non-vitamin K antagonist oral anticoagulants versus well-managed warfarin with a lower INR target of 1.5 to 2.5 in Asians patients with non-valvular atrial fibrillation. <b>2019</b> , 14, e0213517			2
182	Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in octogenarian patients with non-valvular atrial fibrillation. <b>2019</b> , 14, e0211766			17
181	Development of Multidisciplinary Anticoagulation Management Guidelines for Patients Receiving Durable Mechanical Circulatory Support. <b>2019</b> , 25, 1076029619837362			4
180	Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: Insights from the GARFIELD-AF registry. <b>2019</b> , 42, 553-560			12
179	Impact of serum albumin levels on supratherapeutic PT-INR control and bleeding risk in atrial fibrillation patients on warfarin: A prospective cohort study. <b>2019</b> , 22, 111-116			7
178	Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e010510	6		24
177	Impact of time in therapeutic range after left ventricular assist device placement: a comparison between thrombus and thrombus-free periods. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 47, 361-368	5.1		8
176	Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. <i>BMJ Open</i> , <b>2019</b> , 9, e033712	3		0
175	New warfarin anticoagulation management model after heart valve surgery: rationale and design of a prospective, multicentre, randomised trial to compare an internet-based warfarin anticoagulation management model with the traditional warfarin management model. <i>BMJ Open</i> , <b>2019</b> , 9, e032949	3		3
174	Assessment of agreement and time in therapeutic range of capillary versus venous international normalised ratio in frail elderly people in a nursing home. <b>2019</b> , 49, 1442-1446			0

173	Increasing Time in Therapeutic Range of Tacrolimus in the First Year Predicts Better Outcomes in Living-Donor Kidney Transplantation. <b>2019</b> , 10, 2912		5
172	Predictors for INR-control in a well-managed warfarin treatment setting. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 47, 227-232	5.1	8
171	Warfarin Absorption in Short Bowel Syndrome. <b>2019</b> , 35, 43-44		1
170	Six months two years of oral anticoagulation after a first episode of unprovoked deep-vein thrombosis. The PADIS-DVT randomized clinical trial. <b>2019</b> , 104, 1493-1501		14
169	Cost-effectiveness for prevention of thromboembolism by anticoagulants in non-valvular atrial fibrillation: additional analysis from the Hokuriku-Plus AF Registry. <b>2019</b> , 34, 1024-1030		1
168	Primary care management for patients receiving long-term antithrombotic treatment: A cluster-randomized controlled trial. <b>2019</b> , 14, e0209366		5
167	Feasibility and safety of a 12-week INR follow-up protocol over 2 years in an anticoagulation clinic: a single-arm prospective cohort study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 47, 200-208	5.1	4
166	Risk factors for post-thrombotic syndrome in patients with deep vein thrombosis: from the COMMAND VTE registry. <b>2019</b> , 34, 669-677		12
165	Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. <b>2019</b> , 12, 139-148		57
164	D-dimer levels at diagnosis and long-term clinical outcomes in venous thromboembolism: from the COMMAND VTE Registry. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 49, 551-561	5.1	5
163	Algorithm for predicting low maintenance doses of warfarin using age and polymorphisms in genes CYP2C9 and VKORC1 in Brazilian subjects. <b>2020</b> , 20, 104-113		8
162	Non-genetic factors and polymorphisms in genes CYP2C9 and VKORC1: predictive algorithms for TTR in Brazilian patients on warfarin. <b>2020</b> , 76, 199-209		3
161	Effect of multidose drug dispensing on the time in therapeutic range in patients using vitamin-K antagonists: A randomized controlled trial. <b>2020</b> , 18, 70-78		3
160	Effects of vitamin K1 treatment on plasma concentrations of long-acting anticoagulant rodenticide enantiomers following inhalation of contaminated synthetic cannabinoids. <b>2020</b> , 58, 716-724		6
159	Quality Improvement Program Improves Time in Therapeutic Range for Hemodialysis Recipients Taking Warfarin. <b>2020</b> , 5, 159-164		3
158	New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF. <b>2020</b> , 6, 301-309		15
157	Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study. <i>BMJ Open</i> , <b>2020</b> , 10, e038194	3	4
156	In-home Compared With In-Clinic Warfarin Therapy Monitoring in Mechanical Heart Valves: A Population-Based Study. <b>2020</b> , 4, 511-520		1

155	Management of anticoagulant therapy using a portable point-of-care international normalized ratio device and social networking service in a patient with a left ventricular assist device. <b>2020</b> , 22, 156-158		
154	Evaluation of the Validity of SAME-TTR Score in a Cohort of Venous Thromboembolism Patients Treated With Warfarin. <b>2020</b> , 26, 1076029620945039		1
153	Effect of switching from acenocoumarol to phenprocoumon on time in therapeutic range and INR variability: A cohort study. <b>2020</b> , 15, e0235639		2
152	Is the time in therapeutic range on coumarins predicted by previous time in therapeutic range?. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2020</b> , 4, 604-609	5.1	2
151	Impact of estimated glomerular filtration rate on long-term clinical outcomes among Chinese patients with atrial fibrillation. <b>2020</b> , 20, 490		2
150	Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register. <i>BMJ Open</i> , <b>2020</b> , 10, e040449	3	5
149	Evaluation of the Long-Term Impact on Quality After the End of Pharmacist-Driven Warfarin Therapy Management in Patients With Poor Quality of Anticoagulation Therapy. <b>2020</b> , 11, 1056		0
148	The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction. <b>2021</b> , 7, 398-404		36
147	Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism-Results from the thrombEVAL Study. <b>2020</b> , 9,		1
146	Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation. <i>BMJ Open</i> , <b>2020</b> , 10, e036220	3	2
145	Clinical Outcomes of Direct Oral Anticoagulants and Warfarin in Japanese Patients with Atrial Fibrillation Aged ≥5 Years: A Single-Center Observational Study. <b>2020</b> , 7, 325-335		1
144	Anticoagulation Control of Warfarin in Pharmacist-Led Clinics Versus Physician-Led Clinics: A Prospective Observational Study. <b>2020</b> , 13, 1175-1179		4
143	Health-related quality of life in nonvalvular atrial fibrillation patients with controlled or uncontrolled anticoagulation status. <b>2020</b> , 18, 383		0
142	Time in therapeutic range, quality of life and treatment satisfaction of patients on long-term warfarin for non-valvular atrial fibrillation: a cross-sectional study. <b>2020</b> , 18, 347		1
141	Relationship of adverse events to quality of anticoagulation control in atrial fibrillation patients with diabetes: real-world data from the FANTASIA Registry. <b>2020</b> , 52, 300-309		3
140	Poor Time in Therapeutic Range Control is Associated with Adverse Clinical Outcomes in Patients with Non-Valvular Atrial Fibrillation: A Report from the Nationwide COOL-AF Registry. <b>2020</b> , 9,		12
139	Drug-drug interactions with metronidazole and itraconazole in patients using acenocoumarol. <b>2020</b> , 76, 1457-1464		2
138	Vitamin K Concentration and Cognitive Status in Elderly Patients on Anticoagulant Therapy: A Pilot Study. <b>2020</b> , 2020, 9695324		2

137	Quality of anticoagulant therapy and the incidence of in-stent thrombosis after venous stenting. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2020</b> , 4, 594-603	5.1	1
136	The anti-clot treatment scale (ACTS): validation of the translated Arabic version among patients undergoing warfarin therapy in Saudi Arabia. <b>2020</b> , 18, 215		1
135	Predictive ability of creatinine clearance versus estimated glomerular filtration rate for outcomes in patients with non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry. <b>2020</b> , 29, 100559		2
134	Effect of Gene-Based Warfarin Dosing on Anticoagulation Control and Clinical Events in a Real-World Setting. <b>2019</b> , 10, 1527		4
133	Impact of the Fibrosis-4 Index on Risk Stratification of Cardiovascular Events and Mortality in Patients with Atrial Fibrillation: Findings from a Japanese Multicenter Registry. <b>2020</b> , 9,		14
132	The SAME-TTR score as an indicator of warfarin control for patients with deep vein thrombosis in Queensland, Australia. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 50, 614-618	5.1	1
131	Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study. <b>2020</b> , 15, e0226259		0
130	A cross-sectional evaluation of five warfarin anticoagulation services in Uganda and South Africa. <b>2020</b> , 15, e0227458		10
129	Relationship between the Renal Function and Adverse Clinical Events in Patients with Atrial Fibrillation: A Japanese Multicenter Registry Substudy. <b>2020</b> , 9,		5
128	Quality of initial anticoagulant treatment and risk of CTEPH after acute pulmonary embolism. <b>2020</b> , 15, e0232354		5
127	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. <b>2020</b> , 12,		13
126	Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: clinical outcomes in a single centre cohort after long-term follow-up. <b>2020</b> , 20, 166		2
125	Effect of SAME-TTR score and genetic polymorphism on the quality of anticoagulation control in Qatari patients treated with warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 49, 659-666	5.1	1
124	A clinical audit of oral anticoagulant therapy in aged care residents with atrial fibrillation. <b>2020</b> , 42, 474-481		
123	Functionally Significant Coumarin-Related Variant Alleles and Time to Therapeutic Range in Chilean Cardiovascular Patients. <b>2020</b> , 26, 1076029620909154		3
122	Evaluation of Warfarin Use in Patients With Mental Health Conditions in a Rural Community Health Center System. <b>2021</b> , 37, 17-22		0
121	An observational study of international normalized ratio control according to NICE criteria in patients with non-valvular atrial fibrillation: the SAIL Warfarin Out of Range Descriptors Study (SWORDS). <b>2021</b> , 7, 40-49		6
120	Genetic Polymorphism Effect on Warfarin-Rifampin Interaction: A Case Report and Review of Literature. <b>2021</b> , 14, 149-156		1



119	Cost saving analysis of specialized, eHealth-based management of patients receiving oral anticoagulation therapy: Results from the thrombEVAL study. <i>Scientific Reports</i> , <b>2021</b> , 11, 2577	4.9	0
118	Comparison of clinical outcomes between multiple antithrombotic therapy versus left atrial appendage occlusion with dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation. <b>2021</b> , 16, e0244723		0
117	Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies: The Influence of TAC Exposure and Metabolism. <b>2021</b> , 10,		1
116	The efficacy and safety of Hirudin plus Aspirin versus Warfarin in the secondary prevention of Cardioembolic Stroke due to Nonvalvular Atrial Fibrillation: A multicenter prospective cohort study. <b>2021</b> , 18, 1167-1178		1
115	Development and Implementation of National Time in Therapeutic Range Reports and Establishing Quality Standards Within Veterans Health Administration. <b>2021</b> , 36, 1418-1421		0
114	Influence of renal insufficiency on anticoagulant effects and safety of warfarin in Chinese patients: analysis from a randomized controlled trial. <b>2021</b> , 394, 1275-1283		1
113	Time in Therapeutic Range Using a Nomogram for Dose Adjustment of Warfarin in Patients on Hemodialysis With Atrial Fibrillation. <b>2021</b> , 8, 20543581211046079		
112	Which is the best for the warfarin monitoring: Following up by fixed or variable physician?. <b>2022</b> , 9, 93-101		
111	Impact of Blood Pressure Visit-to-Visit Variability on Adverse Events in Patients With Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e018585	6	1
110	Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study). <b>2021</b> , 18,		1
109	Pharmacist-physician collaborative care for outpatients with left ventricular assist devices using a cloud-based home medical management information-sharing system: a case report. <b>2021</b> , 7, 5		
108	Comparison of the Efficacy and Safety Outcomes of Edoxaban in 8040 Women Versus 13 065 Men With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. <b>2021</b> , 143, 673-684		2
107	Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA-LEA noninterventional studies. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, 426-438	5.1	3
106	Epidemiological characteristics, management, and outcomes of atrial fibrillation in TUNISIA: Results from the National Tunisian Registry of Atrial Fibrillation (NATURE-AF). <b>2021</b> , 44, 501-510		2
105	Comparison of Anticoagulation Quality between Acenocoumarol and Warfarin in Patients with Mechanical Prosthetic Heart Valves: Insights from the Nationwide PLECTRUM Study. <b>2021</b> , 26,		4
104	Pharmacogenetics of Anticoagulation and Clinical Events in Warfarin-Treated Patients: A Register-Based Cohort Study with Biobank Data and National Health Registries in Finland. <b>2021</b> , 13, 183-195		4
103	Evaluating the effects of socioeconomic status on stroke and bleeding risk scores and clinical events in patients on oral anticoagulant for new onset atrial fibrillation. <b>2021</b> , 16, e0248134		0
102	Effectiveness of the Alfalfa App in Warfarin Therapy Management for Patients Undergoing Venous Thrombosis Prevention and Treatment: Cohort Study. <b>2021</b> , 9, e23332		3

101	Examining therapeutic equivalence between branded and generic warfarin in Brazil: The WARFA crossover randomized controlled trial. <b>2021</b> , 16, e0248567	
100	Low Quality of Warfarin Therapy is Associated With Female Gender but Not With Polypharmacy in Patients With Atrial Fibrillation. <b>2021</b> , 12, 651799	
99	Drive-up INR testing and phone-based consultations service during COVID-19 pandemic in a pharmacist-lead anticoagulation clinic in Qatar: Monitoring, clinical, resource utilization, and patient- oriented outcomes. <b>2021</b> , 4, 1117	0
98	Ignoring instead of chasing after coagulation factor VII during warfarin management: an interrupted time series study. <b>2021</b> , 137, 2745-2755	1
97	Clinical Implications of Tacrolimus Time in Therapeutic Range and Inpatient Variability in Urban Renal Transplant Recipients Undergoing Early Corticosteroid Withdrawal. <b>2021</b> , 7, e698	0
96	Many Good Reasons to Switch From Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation. <b>2021</b> , 10,	1
95	Physician-Pharmacist Collaborative Clinic Model to Improve Anticoagulation Quality in Atrial Fibrillation Patients Receiving Warfarin: An Analysis of Time in Therapeutic Range and a Nomogram Development. <b>2021</b> , 12, 673302	1
94	Impact of Protocolized Pharmacist Intervention on Critical Activated Partial Thromboplastin Time Values With Heparin Infusions. <b>2021</b> , 37, 225-233	
93	Evaluation of a Pharmacist-Led Remote Warfarin Management Model Using a Smartphone Application (Yixing) in Improving Patients Knowledge and Outcomes of Anticoagulation Therapy. <b>2021</b> , 12, 677943	0
92	Prophylactic anticoagulants to prevent venous thromboembolism in patients with nephrotic syndrome-A retrospective observational study. <b>2021</b> , 16, e0255009	1
91	Comparison among random forest, logistic regression, and existing clinical risk scores for predicting outcomes in patients with atrial fibrillation: A report from the J-RHYTHM registry. <b>2021</b> , 44, 1305-1315	4
90	Patient portal engagement and diabetes management among new portal users in the Veterans Health Administration. <b>2021</b> , 28, 2176-2183	0
89	New Internet-Based Warfarin Anticoagulation Management Approach After Mechanical Heart Valve Replacement: Prospective, Multicenter, Randomized Controlled Trial. <b>2021</b> , 23, e29529	1
88	Evaluation of a pharmacist vs. Haematologist-managed anticoagulation clinic: A retrospective cohort study. <b>2021</b> , 29, 1173-1180	
87	Evaluation of the "safe multidisciplinary app-assisted remote patient-self-testing (SMART) model" for warfarin home management during the COVID-19 pandemic: study protocol of a multi-center randomized controlled trial. <b>2021</b> , 21, 875	0
86	Validation of a Knowledge Test in Turkish Patients on Warfarin Therapy at an Ambulatory Anticoagulation Clinic. <b>2021</b> , 18, 445-451	0
85	Tele-pharmacy Anticoagulation Clinic During COVID-19 Pandemic: Patient Outcomes. <b>2021</b> , 12, 652482	2
84	Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH). <b>2021</b> , 16, e0251665	0

83	Patterns of chronic and transient hyperkalaemia and clinically important outcomes in patients with chronic kidney disease.. <b>2022</b> , 15, 153-161		2
82	Time in Therapeutic Range Significantly Impacts Survival and Adverse Events in Destination Therapy Patients. <b>2021</b> ,		0
81	Antithrombotic therapy in patients with liver disease: population-based insights on variations in prescribing trends, adherence, persistence and impact on stroke and bleeding. <b>2021</b> , 10, 100222		1
80	Anticoagulation Quality of Warfarin and the Role of Physician-Pharmacist Collaborative Clinics in the Treatment of Patients Receiving Warfarin: A Retrospective, Observational, Single-Center Study. <b>2020</b> , 11, 605353		2
79	Prediction Score for Anticoagulation Control Quality Among Older Adults. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	18
78	Control of Anticoagulation Therapy in Patients with Atrial Fibrillation Treated with Warfarin: A Study from the Chinese Atrial Fibrillation Registry. <b>2019</b> , 25, 4691-4698		8
77	Efficacy and safety of vitamin K-antagonists (VKA) for atrial fibrillation in non-dialysis dependent chronic kidney disease. <b>2014</b> , 9, e94420		31
76	Comorbidities against quality control of VKA therapy in non-valvular atrial fibrillation: a French national cross-sectional study. <b>2015</b> , 10, e0119043		20
75	The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. <b>2015</b> , 10, e0122520		52
74	A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation. <b>2015</b> , 10, e0145318		23
73	Use of the SAME-TT2R2 Score to Predict Good Anticoagulation Control with Warfarin in Chinese Patients with Atrial Fibrillation: Relationship to Ischemic Stroke Incidence. <b>2016</b> , 11, e0150674		30
72	Comparison of the Risk of Gastrointestinal Bleeding among Different Statin Exposures with Concomitant Administration of Warfarin: Electronic Health Record-Based Retrospective Cohort Study. <b>2016</b> , 11, e0158130		10
71	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. <b>2016</b> , 11, e0164076		90
70	Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study. <b>2017</b> , 12, e0181000		22
69	Atrial Fibrillation and Cardiovascular Comorbidities, Survival and Mortality: A Real-Life Observational Study. <b>2014</b> , 5, 12-22		2
68	Identification of environmental and genetic factors that influence warfarin time in therapeutic range. <b>2020</b> , 43, e20190025		3
67	Age is associated with time in therapeutic range for warfarin therapy in patients with atrial fibrillation. <b>2016</b> , 7, 54194-54199		11
66	Time in the Therapeutic Range (TTR): An Overly Simplified Conundrum. <b>2017</b> , 8, 2643-2646		5

65	Variability in the Calculation of Time in Therapeutic Range for the Quality Control Measurement of Warfarin. <b>2018</b> , 9, 3428-3434		3
64	TTR: Time in Therapeutic Range or "The Troublesome Report"?. <b>2019</b> , 10, 3469-3470		1
63	Evaluation of a Health Information Technology-Enabled Panel Management Platform to Improve Anticoagulation Control in a Low-Income Patient Population: Protocol for a Quasi-Experimental Design. <b>2020</b> , 9, e13835		1
62	Effective and Safe Management of Oral Anticoagulation Therapy in Patients Who Use the Internet-Accessed Telecontrol Tool SintromacWeb. <b>2015</b> , 4, e10		4
61	Supervised patient self-testing of warfarin therapy using an online system. <b>2013</b> , 15, e138		14
60	Design and Rationale of the National Tunisian Registry of Atrial Fibrillation: Protocol for a Prospective, Multicenter Trial. <b>2018</b> , 7, e181		2
59	Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study. <i>Blood Transfusion</i> , <b>2020</b> , 18, 486-495	3.6	5
58	Best quality indicator of vitamin K antagonist therapy to predict mortality and bleeding in haemodialysis patients with atrial fibrillation. <i>Blood Transfusion</i> , <b>2021</b> , 19, 487-494	3.6	2
57	Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With and Polymorphisms. <b>2019</b> , 10, 1620		1
56	Impact of Anticoagulation Intensity in Korean Patients with Atrial Fibrillation: Is It Different from Western Population?. <b>2020</b> , 50, 163-175		3
55	Anticoagulation control among patients with nonvalvular atrial fibrillation: A single tertiary cardiac center experience. <b>2017</b> , 8, 14-18		7
54	Quality of anticoagulation with warfarin in rural Chhattisgarh, India. <b>2020</b> , 152, 303-307		1
53	The Prevalence and Risks of Inappropriate Combination of Aspirin and Warfarin in Clinical Practice: Results From WARFARIN-TR Study. <b>2019</b> , 36, 17-22		7
52	The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: WARFARIN-TR. <b>2016</b> , 16, 595-600		11
51	Lack of Association of Clinical Factors (SAME-TT2R2) with CYP2C9/VKORC1 Genotype and Anticoagulation Control Quality. <b>2015</b> , 17, 192-8		10
50	Evaluation of Time in Therapeutic Range (TTR) in Patients with Non-Valvular Atrial Fibrillation Receiving Treatment with Warfarin in Tehran, Iran: A Cross-Sectional Study. <b>2016</b> , 10, FC04-FC06		11
49	Stability of vitamin K antagonist anticoagulation after COVID-19 diagnosis. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, e12597	5.1	1
48	Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. <b>2021</b> ,		4

47	Replacement of traditional prothrombin time monitoring with the new Fiix prothrombin time increases the efficacy of warfarin without increasing bleeding. A review article. <b>2021</b> , 19, 72		0
46	Anticoagulant prescribing for atrial fibrillation and risk of incident dementia. <b>2021</b> , 107, 1898-1904		1
45	Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA. <b>2021</b> , 1		2
44	Clinical phenotypes of patients with non-valvular atrial fibrillation as defined by a cluster analysis: A report from the J-RHYTHM registry. <b>2021</b> , 37, 100885		0
43	Oral anticoagulant therapy and bleeding events with vitamin K antagonists in patients with atrial fibrillation in a Hungarian county hospital. <b>2015</b> , 21, 518-25		2
42	Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics. <b>2017</b> , 18, 328-333		2
41	Anticoagulation with Warfarin: Roles of Adherence, Social Support and Illness Perception. <b>2019</b> , 10,		0
40	Association between transportation barriers and anticoagulation control among an inner-city, low-income population: A prospective observational cohort study. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, e12605	5.1	1
39	SAME-TT2R2 score for prediction of suboptimal time in therapeutic range in a Thai population with atrial fibrillation. <b>2020</b> , 61, 641-646		1
38	Clinical profile and management of rivaroxaban in patients with atrial fibrillation in routine practice in Spain: data from six nationwide studies. <b>2019</b> , 8, 212606		0
37	Anticoagulation Therapy in Patients with Non-valvular Atrial Fibrillation in a Private Setting in Brazil: A Real-World Study. <b>2020</b> , 114, 457-466		4
36	The Impact of a Pharmacist-led Warfarin Educational Video in a Saudi Setting. <b>2020</b> , 12, 413-422		1
35	Anticoagulation Control, Outcomes, and Associated Factors in Patients with Atrial Fibrillation Receiving Warfarin at Tertiary Care Hospital in Ethiopia. <b>2021</b> , 27, 10760296211049786		0
34	Pharmacists Interventions improve health-related quality of life of rural older person on warfarin: a randomized controlled trial. <i>Scientific Reports</i> , <b>2021</b> , 11, 21897	4.9	3
33	Comparison of Long-Term Outcomes Between Combination Antiplatelet and Anticoagulant Therapy and Anticoagulant Monotherapy in Patients With Atrial Fibrillation and Left Atrial Thrombi. <b>2020</b> , 2, 457-465		
32	Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. <i>Cmaj</i> , <b>2003</b> , 169, 293-8	3.5	54
31	The safety and adequacy of antithrombotic therapy for atrial fibrillation: a regional cohort study. <i>British Journal of General Practice</i> , <b>2006</b> , 56, 697-702	1.6	22
30	Warfarin 2.0--a computer program for warfarin management. Design and clinical use. <b>1994</b> , 846-50		1

29	Early and late effects of coumarin therapy started before percutaneous coronary intervention: Clinical, angiographic and cost-effective outcome of the Balloon Angioplasty and Anticoagulation Study (BAAS). <i>Netherlands Heart Journal</i> , <b>2002</b> , 10, 235-240	2.2	
28	Evaluation of a pharmacist-managed anticoagulation clinic: Improving patient care. <i>Open Medicine</i> , <b>2009</b> , 3, e16-21		22
27	Safety and effectiveness of point-of-care monitoring devices in patients on oral anticoagulant therapy: a meta-analysis. <i>Open Medicine</i> , <b>2007</b> , 1, e131-46		9
26	Monitoring of international normalized ratios: comparison of community nurses with family physicians. <i>Canadian Family Physician</i> , <b>2012</b> , 58, e465-71	0.9	7
25	Effect of Oral Anticoagulant Therapy on Coagulation Activity and Inflammatory Markers in Patients with Atrial Fibrillation Undergoing Ablation: A Randomized Comparison between Dabigatran and Warfarin. <i>Iranian Journal of Pharmaceutical Research</i> , <b>2013</b> , 12, 945-53	1.1	6
24	Well-managed warfarin is superior to NOACs. <i>Canadian Family Physician</i> , <b>2015</b> , 61, 23-4	0.9	6
23	Time in therapeutic range: Warfarin anticoagulation for atrial fibrillation in a community-based practice. <i>Canadian Family Physician</i> , <b>2017</b> , 63, e425-e431	0.9	17
22	Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico. <i>Puerto Rico Health Sciences Journal</i> , <b>2017</b> , 36, 165-172	0.5	1
21	Anticoagulation Management Outcomes in Veterans: Office vs Telephone Visits. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , <b>2017</b> , 34, 37-40	0.7	
20	Impact of gene polymorphism on the initiation and maintenance phases of warfarin therapy in Chinese patients undergoing heart valve replacement. <i>American Journal of Translational Research (discontinued)</i> , <b>2019</b> , 11, 2507-2515	3	4
19	Quality of warfarin management in primary care: Determining the stability of international normalized ratios using a nationally representative prospective cohort. <i>Canadian Family Physician</i> , <b>2019</b> , 65, 416-425	0.9	8
18	[Pharmacist-led anticoagulation monitoring can significantly improve the effectiveness and safety of warfarin for patients during hospitalization]. <i>Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University</i> , <b>2020</b> , 40, 544-549	0.5	1
17	Patients' satisfaction associated with portable coagulometers for warfarin monitoring: a cross-sectional study. <i>Blood Transfusion</i> , <b>2020</b> , 18, 386-395	3.6	
16	Optimal INR level in elderly and non-elderly patients with atrial fibrillation receiving warfarin: a report from the COOL-AF nationwide registry in Thailand. <i>Journal of Geriatric Cardiology</i> , <b>2020</b> , 17, 612-620	1.7	
15	Adherence to rivaroxaban for the treatment of venous thromboembolism-Results from the FIRST registry. <i>Research and Practice in Thrombosis and Haemostasis</i> , <b>2021</b> , 5, e12614	5.1	0
14	Differences in Secure Messaging, Self-management, and Glycemic Control Between Rural and Urban Patients: Secondary Data Analysis. <i>JMIR Diabetes</i> , <b>2021</b> , 6, e32320	2.7	0
13	Incremental Value of Genotype Bins over the HAS-BLED Score for the Prediction of Bleeding Risk in Warfarin-Treated Patients with Atrial Fibrillation. <i>Cardiology Research and Practice</i> , <b>2021</b> , 2021, 9030005	1.9	
12	Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e020904	6	1

11	Incidence and risk factors for thromboembolism and major bleeding in patients with mechanical heart valves: a tertiary hospital-based study in Botswana. <i>Cardiovascular Journal of Africa</i> , <b>2020</b> , 31, 185-189	0.7	1
10	Rate Control Versus Rhythm Control in Patients with Left Ventricular Assist Devices and Atrial Fibrillation.. <i>Journal of Atrial Fibrillation</i> , <b>2021</b> , 13, 20200474	0.8	
9	Efficacy and safety of app-based remote warfarin management during COVID-19-related lockdown: a retrospective cohort study.. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2022</b> , 1	5.1	0
8	Therapeutic-Dose Warfarin (International Normalized Ratio >1.6) Plus Aspirin Improved Long-Term Patency of Saphenous Vein Graft without Bleeding Complication.. <i>Annals of Thoracic and Cardiovascular Surgery</i> , <b>2022</b> , 28,	1.8	
7	Virtual Education for Patient Self-Testing for Warfarin Therapy Is Effective During the COVID-19 Pandemic.. <i>Joint Commission Journal on Quality and Patient Safety</i> , <b>2022</b> , 48, 214-214	1.4	0
6	Vitamin K-dependent anticoagulant use and level of anticoagulation control in sub-Saharan Africa: protocol for a retrospective cohort study.. <i>BMJ Open</i> , <b>2022</b> , 12, e057166	3	
5	The Role of Intra-Patient Variability of Tacrolimus Drug Concentrations in Solid Organ Transplantation: A Focus on Liver, Heart, Lung and Pancreas.. <i>Pharmaceutics</i> , <b>2022</b> , 14,	6.4	0
4	The Rate of Clinical Outcomes in Atrial Fibrillation according to Antithrombotic Strategy: The COOL-AF Registry.. <i>Cardiovascular Therapeutics</i> , <b>2022</b> , 2022, 5797257	3.3	
3	The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists.. <i>Thrombosis and Haemostasis</i> , <b>2022</b> , 122, 377-385	7	0
2	Relation of the Atrial Fibrillation Better Care (ABC) Pathway to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists.. <i>Journal of Personalized Medicine</i> , <b>2022</b> , 12,	3.6	0
1	The effectiveness of split tablet dosing versus alternate-day dosing of warfarin: a randomized control trial.. <i>Scientific Reports</i> , <b>2021</b> , 11, 24060	4.9	